Research programme: pantazines - CoA Therapeutics
Alternative Names: Pantazines; SJ-18-0046Latest Information Update: 28 Aug 2023
At a glance
- Originator St. Jude Childrens Research Hospital
- Developer CoA Therapeutics; St. Jude Childrens Research Hospital
- Class Small molecules
- Mechanism of Action Pantothenate kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Propionic acidaemia
- No development reported Pantothenate kinase-associated neurodegeneration
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for research development in Pantothenate Kinase Associated Neurodegeneration in USA (PO)
- 01 Jan 2022 Preclinical trials in Propionic acidaemia in USA (PO) before January 2021
- 24 Dec 2021 CoA Therapeutics licensed Research programme: pantazines - CoA Therapeutics from St. Jude Children's Research Hospital as of 24 Dec 2021. https://www.stjude.org/